A phase I clinical study of Nimorazole as a hypoxic radiosensitizer.
Nimorazole, a 5-Nitromidazole compound has been shown in animal studies to have similar radiosensitizing properties to misonidazole at clinically acceptable dose levels. The drug is well absorbed in humans after oral administration with peak plasma levels occurring around 90 min after ingestion (range 35-135 min) and a plasma half life between 2 and 4.8 hours. Total doses of Nimorazole up to 60 grams given in daily doses with conventional radiation therapy have demonstrated a significant lack of side effects, in particular no demonstrable neurotoxicity.
D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000378:metabolism*; D009554:Nimorazole / Q000097:blood / Q000378:metabolism* / Q000633:toxicity; D009593:Nitroimidazoles / Q000378:metabolism*; D011838:Radiation-Sensitizing Agents / Q000097:blood / Q000378:metabolism* / Q000633:toxicity; D013997:Time Factors
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; D009554:Nimorazole